Tag: inhibitor

Recently, a research team led by Profs. Liu Qingsong and Liu Jing from the Institute of Health & Medical Technology of the Hefei Institutes of Physical Science (HFIPS) discovered a potent and selective PI3Kδ inhibitor IHMT-PI3Kδ-372, effective against chronic obstructive pulmonary disease (COPD) in vivo. COPD is a chronic progressive respiratory disease characterized by airflow

The checkpoint inhibitor pembrolizumab (Keytruda) increases the survival time of patients with advanced head and neck cancers, according to a new global study led by Yale Cancer Center (YCC). The data was published today in the journal The Lancet. The findings of the phase 3 study show that, compared to the standard therapy, overall survival

About one in 8,000 people have facioscapulohumeral muscular dystrophy, according to a 2014 study, which is relatively common in the world of genetic diseases. New University of Minnesota Medical School research identifies an inhibitor that protects cells from toxic effects associated with this disease in cells and mice. Facioscapulohumeral muscular dystrophy (FSHD) is a genetic

A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of

(HealthDay)—The selective Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, according to a study published May 10 in the New England Journal of Medicine to coincide with the annual meeting of the

TUESDAY, Oct. 9, 2018 — Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in the Oct. 4 issue of the New England Journal of Medicine. Kim Papp, M.D.,

A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for breast cancer. In their report published in the Annals of Oncology, the team—led by investigators at Massachusetts General Hospital (MGH), Institute Gustave Roussy in Paris, and Texas Oncology-Baylor Sammons Cancer Center/U.S. Oncology in Dallas—reports